Background: Glia activation is thought to contribute to neuronal damage in several neurodegenerative diseases based on preclinical and human post-mortem studies, but its role in primary lateral sclerosis (PLS) is unknown.
Introduction
Glia activation has been implicated in the pathogenesis of several neurodegenerative diseases based on both pre-clinical and human post-mortem studies. For instance, glia activation has been detected in animal models and human CNS autopsy tissue in Alzheimer's disease (AD) [1] [2] [3] , amyotrophic lateral sclerosis (ALS) 4, 5 , multiple sclerosis (MS) 5, 6 and Huntington's disease (HD) 6, 7 . Work in mouse models of ALS suggest that glia activation contributes to disease progression and neurotoxicity [8] [9] [10] . ALS is a form of motor neuron disease (MND) where both the upper and lower motor neurons are progressively lost whereas primary lateral sclerosis (PLS) is an MND that predominantly affects the neurons that arise from the motor cortex (Upper Motor Neurons, UMNs) 11 . The role of glia activation in PLS is unknown.
Glia activation can be tracked in vivo by using PET radiotracers such as [ 11 C]-PBR28 that bind to the 18 kDa translocator protein (TSPO). [ 11 C]-PBR28 uptake is low in healthy brain tissue, but is increased in the setting of microglia activation and reactive astrocytosis 12 . Further, PET can be combined with magnetic resonance (MR) techniques to assess white matter integrity (diffusion tensor imaging or DTI) and neuronal loss (morphometric analyses). This type of multimodal neuroimaging can deliver a snapshot of complex disease mechanisms in vivo and may represent a novel tool to track disease severity, progression, and response to candidate treatments. Indeed, there is growing interest in multimodal neuroimaging across neurologic disease as shown by recent proof-of-concept studies suggesting that MR-PET can be used to identify glia activation and its relationship to neuronal loss and structural abnormalities in AD 3, 13 , ALS [14] [15] [16] [17] , HD 18, 19 , and in populations with a history of concussion or moderate-to-severe traumatic brain injury [20] [21] [22] .
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A C C E P T E D M A N U S C R I P T 8 While the course of PLS is slower and the prognosis is more favorable than ALS, it still leads to progressive disability including difficulty walking, difficulty performing activities of daily living, dysarthria, and dysphagia. There are no available treatments that slow down PLS disease progression. Further, there are no animal models of PLS, no available biomarkers, and patients with PLS are usually excluded from ALS clinical trials because it is unclear if they share the same pathophysiology. Elucidating in vivo disease mechanisms is clearly an unmet need for this orphan disease. Here we employed MR-PET to test the hypothesis that people with PLS have increased glia activation in the motor regions, and that glia activation co-localizes and correlates with cortical thinning (suggestive of neuronal loss) and white matter dysfunction. The hypothesis is anchored on autopsy reports from PLS patients showing glia proliferation surrounding areas of motor neuron loss in the motor cortices [23] [24] [25] .
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Study participants
Ten individuals with PLS (7 men, 3 women; mean age [SD] in years, 62 [8.5] ) and ten age-matched healthy controls (5 men, 5 women; mean age [SD] in years, 54 [11.3] ) were included in the study. To meet inclusion criteria, PLS participants had to meet Pringle's criteria for the diagnosis of PLS 25 . Diagnosis was confirmed at enrollment by a physician with subspecialty training in Neuromuscular Medicine and expertise in PLS. Since the Ala147Thr polymorphism in the TSPO gene imparts a trimodal pattern of binding affinity to second generation TSPO ligands such as [ 11 C]-PBR28 26 , the participants in both groups were genotyped for this polymorphism at screening in order to exclude low affinity binders (Thr/Thr), and to match the proportion of high-(Ala/Ala) and mixed-affinity binders (Ala/Thr) across groups (4 and 6, respectively in both groups). The study was approved by the Partners Human Research Committee and the Radioactive Drug Research Committee. All participants provided written informed consent.
Clinical assessments
Clinical assessment included the revised ALS functional rating scale (ALSFRS-R) 27 Table 1 . 
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MR-PET Imaging
All participants had simultaneous MR-PET imaging using the radiotracer [ 11 C]-PBR28.
[ 11 C]-PBR28 was produced in-house as previously described 28 
MR-PET Data Analyses
FreeSurfer version 6.0 tools were used for T1 image pre-processing including reconstruction, parcellation of cortical surfaces, and segmentation of sub-cortical regions.
FreeSurfer was used to perform surface-based analyses (SBA). The FMRIB software library (FSL, v.5.0.9; Oxford, UK) was used to create diffusion maps for fractional anisotropy (FA) and diffusivities (mean MD, axial AD, and radial RD). Preprocessing steps of diffusion data including motion evaluation were conducted as previously reported 15 . [ 11 C]-PBR28 PET data was reconstructed as previously described 14 . Standardized uptake value (SUV) normalized to
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12 whole brain mean (SUVR) from 60-90 min post time of injection were used to assess TSPO expression (SUVR 60-90min ). Finally, the individual SUVR 60-90min images were registered to the standard MNI template (Montreal Neurological Institute MNI152) to conduct between-group analyses.
Statistical analyses:
Voxel-wise SUVR analysis:
SUVR 60-90min images in MNI152 standard space were fed into a voxel-wise between-groups analysis. Non-parametric permutation inference was performed using 5,000 permutations and threshold-free cluster enhancement (TFCE). The resultant statistical maps were family-wise error (FWE) adjusted (p FWE < 0.05) to correct for multiple comparisons. General linear model (GLM) was used in the voxel-wise analyses and covariates were added to adjust for the effect of age, sex and [ 11 C]-PBR28 binding affinity.
Surface-based analyses (SBAs):
SBAs were employed to investigate the difference between groups in cortical thickness and [ 11 C]-PBR28 uptake. The analyses were conducted in the pial surface (which follows the border between gray matter and cerebrospinal fluid), as well as in sub-cortical white matter surface (which follows the border between white and gray matter). For SBA analysis of cortical thickness, age and sex were entered as covariates while for SBA of PET data, age, sex and [ 11 C]-PBR28 binding affinity were entered as covariates.
Cortical thickness processed in FreeSurfer version 6.0 and smoothed at full width at half maximum (FWHM)=6mm was then fed into SBA. The resultant statistical maps were clusterwise corrected for multiple comparisons using Monte Carlo simulation.
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SBA of SUVR was performed using PET Surfer, a set of tools within FreeSurfer version 6.0 that include correction of partial volume effects. The resultant SUVR images resampled onto brain surface were then smoothed at (FWHM=6 mm) and fed into a GLM analysis to study on surface the difference in [ 11 C]-PBR28 uptake between groups. A projection factor (projfrac) was used in SBA to project the SUVR maps onto the brain surface. The default value for projfrac is between (0 and 1). Zero represents the border line between white and pial. The negative values of the projfrac (e.g. projfrac= -2) means (2*thickness) away from the white surface into the white matter. To define which layer of the brain has the maximum [ 11 C]-PBR28 uptake difference between groups, multiple values of projfrac (+0.5, 0, -0.5, -1, -1.5, -2) were tested in a separate SBA analysis. The resultant SUVR images, which were resampled onto the brain surface, were then organized by group, concatenated together, smoothed at (FWHM=6 mm), and fed into a GLM analysis to study the difference in [ 11 C]-PBR28 uptake between groups on the surface.
Monte Carlo simulation was used to correct data for multiple companions.
Tract-based spatial statistics (TBSS) analysis:
We performed statistical analysis to study differences in FA values between PLS and controls. In this analysis, FA maps were fed into non-parametric permutation inference. Data were permuted (n=5000), threshold free cluster enhancement (TFCE) method was applied, and the p values were FWE adjusted at p=0·05 to correct for multiple comparisons. The anatomical locations were determined by using the JHU White-Matter Tractography and JHU ICBM-DTI-81 White-Matter Labels atlases 29, 30 . GLM was used in TBSS to adjust FA values for the effect of age.
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A Between-groups differences were tested using non-parametric Wilcoxon test. Spearman correlation coefficient was used to investigate the relationship between [ 11 C]-PBR28 uptake and FA within the ROI and clinical measures (ALSFRS-R, UMNB, vital capacity, and disease duration). Effect size (Cohen d and 95% confidence interval (CI)) was calculated based on differences between groups.
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Results
Mean group [ 11 C]-PBR28 uptake and voxel-wise analysis for between-group differences.
Whole brain voxel-wise analysis showed increased [ 11 C]-PBR28 uptake in the motor regions in individuals with PLS compared to healthy controls in both hemispheres ( Figure   1A,B,C,E) . There were no regions for which PLS showed less [ 11 C]-PBR28 uptake than healthy controls. There were no significant right-to-left differences in clinical presentation as measured by UMN Burden scores in this cohort.
Tract-based spatial statistics (TBSS) analysis:
TBSS analysis revealed decreased FA in PLS compared to controls, even after adjusting for age (Figure 1D) Panel E: [ 11 C]-PBR28 uptake (expressed as SUVR 60-90min ) in ten healthy controls (HC) and ten individuals with PLS.
Surface-based (SBA) analyses.
SBA of cortical thickness revealed cortical thinning in PLS compared to HC in the precentral gyri (P<0.01) (Figure 2A) which colocalized with regions of increased [ 11 C]-PBR28 uptake in the subcortical white matter of the motor regions (Figure 2B) . 
Region of interest (ROI) analyses.
The anatomical boundaries of the ROI used in this study are shown in Figure 3A and include the precentral and paracentral gyri bilaterally. In this region, mean [ 11 C]-PBR28 uptake and radial diffusivity were significantly higher in PLS than HC (p<0.05) while FA values were significantly lower (p<0.05) ( Figure 3B ). Diffusivity values (RD, MD, AD) were adjusted to 0 decimals (multiplied by 1000).
Abbreviations: AD: axial diffusivity; CI: confidence interval; FA: fractional anisotropy; MD: mean diffusivity; RD: radial diffusivity; SUVR: standardized uptake value ratio. 
Discussion
Our study demonstrates increased in vivo glia activation in the motor regions in people with PLS, as measured by [ 11 C]-PBR28 PET imaging. [ 11 C]-PBR28 binds to TSPO, whose expression is dramatically upregulated in activated glial cells including microglia and astrocytes 12, 31 . This report represents the first step in the development of [ 11 C]-PBR28 PET as an in vivo PLS biomarker, an approach that is aligned with efforts that are unfolding in other neurologic diseases 21, [32] [33] [34] [35] . The translational potential of these findings is that [ 11 C]-PBR28 PET signal could be further developed as a biomarker to support proof-of-mechanism trials of compounds that target glia activation in PLS.
Our findings are consistent with autopsy reports from PLS patients showing glia proliferation surrounding areas of motor neuron loss in the motor cortices [23] [24] [25] . Increased glia activation overlapped with areas of cortical thinning and white matter abnormalities. Thus, MR-PET can be used to simultaneously capture in vivo molecular and structural changes that underlie PLS disease biology. Cortical thinning and white matter abnormalities have been reported previously in PLS [36] [37] [38] [39] [40] . Here, we confirm these findings and show co-localization with a molecular marker of glia activation.
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There is growing evidence that glia activation and phenotypic changes occur during disease progression of motor neuron disease and that microglia exert both neuroprotective and neurotoxic effects at various stages of the disease [8] [9] [10] 41, 42 . Other glial cells, such as reactive astrocytes, are also proliferated in motor neuron disease 43 . While these glia changes denote the presence of neuroinflammation in the brain, it remains debated whether neuroinflammation drives the initial pathogenesis 8 predictive of future disease progression is not available. Lastly, a potential limitation of the study is the use of SUVR to represent [ 11 C]-PBR28 binding without performing arterial sampling for kinetic modeling. The approach used here has been used successfully in previous studies 14, 15, 35, 44, 45 and is strengthened by recent data showing good correlation between SUVR and DVR computed using radiometabolite-corrected arterial input function 35 .
The area of highest [ 11 C]-PBR28 uptake in PLS was located in the subcortical white matter underlying the motor cortex and was therefore partially outside the a priori ROI based on our previous ALS studies, where maximal [ 11 C]-PBR28 uptake was found in the cortex of the precentral and paracentral gyri 14, 15 . For this reason, the results of the ROI analyses may not describe the full extent of glia activation in PLS. Our study was instrumental in localizing the area of highest [ 11 C]-PBR28 uptake in PLS and will guide future projects to more accurately measure the extent of [ 11 C]-PBR28 uptake in PLS. that require to wait a few years before diagnosing PLS (3 to 4 years depending on whether Pringle 25 or Gordon 46 criteria are used), our cohort comprised individuals whose mean disease duration was about 11 years, well beyond the 2-year disease duration of participants in our previous ALS study 14, 15 . Thus, the lack of an association between imaging metrics and clinical measures may be due to the late observation time, when clinical changes may no longer be associated with some of the mechanisms we investigated with imaging. Future studies are needed to determine the time course of [ 11 C]-PBR28 uptake early after onset of UMN-predominant disease.
In conclusion, we demonstrated that multimodal MR-PET can localize and quantify glia activation in vivo in patients with PLS. We propose that this approach may inform clinical drug development by providing a platform to screen candidate therapeutics that target glia activation.
Large, multi-center, longitudinal studies are needed to validate MR-PET with [ 11 C]-PBR28 as a biomarker for PLS. 
